title: A better therapeutic profile for the combination of mitomycin-C, ifosfamide and cisplatin (MIC) in advanced non-small-cell lung cancer: a useful dose-schedule modification.
abstract: BACKGROUND
  In our previous experience with chemotherapy for non-small-cell lung cancer (NSCLC) the combination of mitomycin, ifosfamide and cisplatin (MIC) showed the highest activity in a three-arm randomized trial; the MIC regimen also yielded the most toxic effects, with 8% WHO grade 2-4 nephrotoxicity, 21% grade 3-4 leukopenia and 10% grade 3-4 thrombocytopenia. In that study cisplatin (120 mg/m2) was delivered on day 1 and ifosfamide and mitomycin on day 2. In an effort to reduce MIC toxicity a modified regimen was tested in a phase II trial: cisplatin 100 mg/m2 was given on day 2 and ifosfamide on day 1 with mitomycin.
  
  
  METHODS
  From November 1993 to December 1995, 70 advanced NSCLC patients entered the trial.
  
  
  RESULTS
  Twenty-nine of 70 patients achieved major response (41%) with 6 complete (9%) and 23 partial remissions (33%). We recorded 4% of WHO grade 3-4 anemia, and 2% of leukopenia and thrombocytopenia.
  
  
  CONCLUSIONS
  We confirmed the activity of the MIC regimen in NSCLC, and the modified schedule seems to substantially improve the safety of the combination.
authors.affiliation: Medical Oncology Division, Policlinico Hospital, Perugia, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Crinò
authors.forename: E
authors.initials: E
authors.lastname: Corgna
authors.forename: S
authors.initials: S
authors.lastname: Porrozzi
authors.forename: M A
authors.initials: MA
authors.lastname: Palladino
authors.forename: S
authors.initials: S
authors.lastname: Darwish
authors.forename: V
authors.initials: V
authors.lastname: Minotti
authors.forename: A M
authors.initials: AM
authors.lastname: Mosconi
authors.forename: M
authors.initials: M
authors.lastname: Tonato
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage
chemical_list: D016685:Mitomycin; D002945:Cisplatin; D007069:Ifosfamide